Zydus and MSN Launch First Generic of Adempas (Riociguat) in U.S.
Zydus Lifesciences and MSN have launched the first generic version of Adempas® (Riociguat) in the U.S. market. This launch provides a lower-cost treatment option for patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Zydus Lifesciences, in partnership with MSN, has launched the first generic version of riociguat, known by the brand name Adempas®, in the United States. This first-to-market generic offering aims to provide a more affordable treatment option for individuals suffering from pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH).
Riociguat is a medication used to treat these specific, serious forms of pulmonary hypertension. The original branded drug, Adempas®, is manufactured by Bayer. The introduction of a generic equivalent is expected to reduce healthcare costs for patients and the system.
While Zydus and MSN have not disclosed specific pricing details or full distribution across all U.S. states, the product became available on October 5, 2026. Access to lower-cost medications is crucial for long-term treatment adherence and affordability.
The availability of generic drugs plays a significant role in managing pharmaceutical expenditures. This collaboration between Zydus and MSN is anticipated to increase competition and potentially lower the overall cost of riociguat therapy in the U.S.